Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Valcyte; Belgium: Valcyte; Bulgaria: Valcyte; Czech Republic: Valcyte; Denmark: Valcyte; Estonia: Valcyte; Finland: Valcyte; France: Rovalcyte; Germany: Valcyte; Hungary: Valcyte; Ireland: Valcyte; Italy: Darilin, Valcyte; Luxembourg: Valcyte; Netherlands: Valcyte, Valixa; Poland: Valcyte; Portugal: Valcyte; Spain: Valcyte; Sweden: Valcyte; UK: Valcyte.

North America

Canada: Valcyte; USA: Valcyte.

Latin America

Argentina: Valixa; Brazil: Valcyte; Mexico: Valcyte.


Japan: Valixa.

Drug combinations


Valganciclovir Hydrochloride: C~14~H~22~N~6~O~5~ HCl. Mw: 390.82. L-Valine, ester with 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine, monohydrochloride. CAS-175865-59-5; CAS-175865-60-8 (valganciclovir)(1997).

Pharmacologic Category

Antivirals; Nucleosides and Nucleotides. (ATC-Code: J05AB14).

Mechanism of action

Rapidly converted to ganciclovir in the body. Ganciclovir is phosphorylated to a substrate which competitively inhibits binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.

Therapeutic use

Treatment of cytomegalovirus retinitis in acquired immunodeficiency syndrome. Prevention of cytomegalovirus (CMV) disease in high-risk patients undergoing kidney, heart, or kidney/pancreas transplantation.

Pregnancy and lactiation implications

Converted to ganciclovir. Ganciclovir may adversely affect spermatogenesis and fertility (mutagenic potential). Contraindicated in nursing women.

Unlabeled use


Hypersensitivity to valganciclovir, ganciclovir, acyclovir, or any component of the formulation. Absolute neutrophil count <500/mm^3^. Platelet count <25000/mm^3^. Hemoglobin <8 g/dL.

Warnings and precautions

Hazardous agent. May cause granulocytopenia, anemia, and/or thrombocytopenia (use with caution in pre-existing bone marrow suppression, cytopenias, or in patients receiving myelosuppressive drugs/irradiation). Ganciclovir may adversely affect spermatogenesis and fertility. Use with caution in renal impairment. Not indicated for use in liver transplant patients (higher incidence of tissue-invasive CMV relative to oral ganciclovir).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart